Geburtshilfe Frauenheilkd 2018; 78(10): 198
DOI: 10.1055/s-0038-1671351
Poster
Freitag, 02.11.2018
Gynäkologische Onkologie VI
Georg Thieme Verlag KG Stuttgart · New York

L1CAM to further stratify endometrial carcinoma patients with nonspecific molecular risk profile

F Kommoss
1  Institut für Pathologie, Universitätsklinikum Heidelberg, Allgemeine Pathologie und path. Anatomie, Heidelberg, Deutschland
,
A Talhouk
2  University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, Kanada
,
F Kommoss
3  Institut für Pathologie im Medizin Campus Bodensee Friedrichshafen, Friedrichshafen, Deutschland
,
FA Taran
4  Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
,
A Staebler
5  Universitätsklinikum Tübingen, Institut für Pathologie, Tübingen, Deutschland
,
B Gilks
2  University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, Kanada
,
D Huntsman
2  University of British Columbia, Department of Pathology and Laboratory Medicine, Vancouver, Kanada
,
B Krämer
4  Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
,
SY Brucker
4  Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
,
J McAlpine
6  University of British Columbia, Department of Gynecology and Obstetrics, Vancouver, Kanada
,
S Kommoss
4  Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
› Author Affiliations
Further Information

Publication History

Publication Date:
20 September 2018 (online)

 

Background:

The newly developed and validated Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently we have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high risk disease in EC. In the current study, it was our aim to determine the prognostic and biological significance of aberrant L1CAM expression in ProMisE subgroups in a large single center EC cohort.

Methods:

ProMisE (POLE/MMR-D/p53 wt/p53 abn) classification results from a previously characterized large population-based cohort of EC were available for further analysis. L1CAM expression was studied by immunohistochemistry (IHC). Association between ProMisE molecular subtypes and L1CAM expression was evaluated using the log-rank test, survival analyses were calculated using cox-regression models.

Results:

97/452 (21%) of EC were L1CAM positive. The distribution of L1CAM positive tumors among ProMisE subtypes was as follows: 7/42 (17%) POLE, 26/127 (21%) of MMR-D, 20/229 (8%) p53 wt and 45/55 (80%) p53 abn. Upon ProMisE subtype analysis, L1CAM status was predictive of worse DSS among p53 wt tumors with a HR of 6.53 (CI 2.26 – 16.85; p < 0.0001). In a multivariate model within the p53 wt subtype subgroup, L1CAM remained a significant prognosticator for DSS [HR 3.54 (CI 1.01 – 11.32)].

Conclusion:

Our study confirms a highly significant correlation between mutation-type p53 immunostaining and abnormal L1CAM expression in EC. Furthermore, L1CAM status may help to further stratify the large p53 wt ProMisE subgroup into tumors with lower and higher malignant potential.